OTCMKTS:AKRXQ

Akorn Competitors

$0.03
0.00 (0.00 %)
(As of 12/17/2020)
Add
Compare
Today's Range
$0.03
Now: $0.03
$0.03
50-Day Range
$0.03
MA: $0.03
$0.03
52-Week Range
$0.01
Now: $0.03
$5.40
VolumeN/A
Average Volume7.44 million shs
Market Capitalization$3.60 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65

Competitors

Akorn (OTCMKTS:AKRXQ) Vs. NVLNF, MCUJF, MDVL, NRIFF, TLGT, and CPMD

Should you be buying AKRXQ stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Akorn, including Novelion Therapeutics (NVLNF), Medicure (MCUJF), MedAvail (MDVL), Nuvo Pharmaceuticals (NRIFF), Teligent (TLGT), and CannaPharmaRX (CPMD).

Akorn (OTCMKTS:AKRXQ) and Novelion Therapeutics (OTCMKTS:NVLNF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.

Earnings & Valuation

This table compares Akorn and Novelion Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Novelion Therapeutics$130.43 million0.11$-108,330,000.00N/AN/A

Novelion Therapeutics has lower revenue, but higher earnings than Akorn.

Volatility and Risk

Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Novelion Therapeutics has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Akorn and Novelion Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Novelion Therapeutics0000N/A

Insider & Institutional Ownership

0.1% of Akorn shares are held by institutional investors. Comparatively, 48.6% of Novelion Therapeutics shares are held by institutional investors. 3.9% of Akorn shares are held by company insiders. Comparatively, 3.6% of Novelion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Akorn and Novelion Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
Novelion TherapeuticsN/AN/AN/A

Summary

Novelion Therapeutics beats Akorn on 7 of the 9 factors compared between the two stocks.

Medicure (OTCMKTS:MCUJF) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Medicure and Akorn's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicure$15.20 million0.89$-14,910,000.00N/AN/A
Akorn$682.43 million0.01$-226,770,000.00N/AN/A

Medicure has higher earnings, but lower revenue than Akorn.

Analyst Ratings

This is a summary of recent ratings for Medicure and Akorn, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medicure0000N/A
Akorn0000N/A

Profitability

This table compares Medicure and Akorn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medicure-179.92%-63.27%-41.85%
Akorn-54.01%-5.13%-0.49%

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 12.9% of Medicure shares are owned by insiders. Comparatively, 3.9% of Akorn shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Medicure has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500.

Summary

Akorn beats Medicure on 6 of the 10 factors compared between the two stocks.

MedAvail (NASDAQ:MDVL) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Earnings and Valuation

This table compares MedAvail and Akorn's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MedAvail$1.03 million13.02$-4,260,000.00($5.52)-2.39
Akorn$682.43 million0.01$-226,770,000.00N/AN/A

MedAvail has higher earnings, but lower revenue than Akorn.

Volatility & Risk

MedAvail has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for MedAvail and Akorn, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MedAvail00203.00
Akorn0000N/A

MedAvail currently has a consensus price target of $20.00, indicating a potential upside of 51.52%. Given MedAvail's higher possible upside, equities analysts clearly believe MedAvail is more favorable than Akorn.

Insider and Institutional Ownership

40.2% of MedAvail shares are held by institutional investors. Comparatively, 0.1% of Akorn shares are held by institutional investors. 45.3% of MedAvail shares are held by company insiders. Comparatively, 3.9% of Akorn shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares MedAvail and Akorn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MedAvail-245.38%-168.39%-104.11%
Akorn-54.01%-5.13%-0.49%

Summary

MedAvail beats Akorn on 7 of the 12 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Nuvo Pharmaceuticals (OTCMKTS:NRIFF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Profitability

This table compares Akorn and Nuvo Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
Nuvo Pharmaceuticals-2.81%8.02%1.11%

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Akorn and Nuvo Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Nuvo Pharmaceuticals$52.41 million0.25$2.53 millionN/AN/A

Nuvo Pharmaceuticals has lower revenue, but higher earnings than Akorn.

Volatility and Risk

Akorn has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Akorn and Nuvo Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Nuvo Pharmaceuticals0000N/A

Summary

Nuvo Pharmaceuticals beats Akorn on 7 of the 10 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and Teligent (NASDAQ:TLGT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Akorn and Teligent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
Teligent-91.50%N/A-17.52%

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. Comparatively, 28.2% of Teligent shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 2.1% of Teligent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Akorn and Teligent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
Teligent$65.90 million0.19$-25,120,000.00N/AN/A

Teligent has lower revenue, but higher earnings than Akorn.

Risk & Volatility

Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Teligent has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akorn and Teligent, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
Teligent01002.00

Teligent has a consensus price target of $2.00, suggesting a potential upside of 244.83%. Given Teligent's higher possible upside, analysts clearly believe Teligent is more favorable than Akorn.

Summary

Teligent beats Akorn on 6 of the 11 factors compared between the two stocks.

Akorn (OTCMKTS:AKRXQ) and CannaPharmaRX (OTCMKTS:CPMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares Akorn and CannaPharmaRX's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Akorn-54.01%-5.13%-0.49%
CannaPharmaRXN/A-726.81%-96.06%

Insider & Institutional Ownership

0.1% of Akorn shares are owned by institutional investors. 3.9% of Akorn shares are owned by company insiders. Comparatively, 71.9% of CannaPharmaRX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Akorn and CannaPharmaRX's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akorn$682.43 million0.01$-226,770,000.00N/AN/A
CannaPharmaRXN/AN/A$-20,450,000.00N/AN/A

CannaPharmaRX has lower revenue, but higher earnings than Akorn.

Risk & Volatility

Akorn has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, CannaPharmaRX has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akorn and CannaPharmaRX, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akorn0000N/A
CannaPharmaRX0000N/A

Summary

Akorn beats CannaPharmaRX on 5 of the 9 factors compared between the two stocks.


Akorn Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NVLNF
Novelion Therapeutics
0.6$0.70flat$13.77 million$130.43 million0.00Gap Down
Medicure logo
MCUJF
Medicure
0.6$1.32flat$13.53 million$15.20 million-1.05Decrease in Short Interest
News Coverage
MedAvail logo
MDVL
MedAvail
1.9$13.20flat$13.41 million$1.03 million-3.23Analyst Report
Increase in Short Interest
NRIFF
Nuvo Pharmaceuticals
0.7$1.14flat$13.00 million$52.41 million28.50Gap Up
Teligent logo
TLGT
Teligent
1.2$0.58flat$12.62 million$65.90 million-0.07News Coverage
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.25flat$12.29 millionN/A-0.48Decrease in Short Interest
CannaPharmaRX logo
CPMD
CannaPharmaRX
0.3$0.25flat$12.29 millionN/A-0.48Decrease in Short Interest
iCo Therapeutics logo
ICOTF
iCo Therapeutics
0.5$0.08flat$11.99 millionN/A-3.90Decrease in Short Interest
BetterLife Pharma logo
BETRF
BetterLife Pharma
0.0$0.67flat$11.46 millionN/A-0.89Increase in Short Interest
Gap Up
Peak Pharmaceuticals logo
PKPH
Peak Pharmaceuticals
0.7$0.15flat$11.36 millionN/A0.00
Acerus Pharmaceuticals logo
TRLPF
Acerus Pharmaceuticals
0.5$0.04flat$10.81 million$7.38 million0.00Gap Down
Tower One Wireless logo
TOWTF
Tower One Wireless
0.0$0.12flat$10.76 million$4.08 million-1.28Increase in Short Interest
Nexien BioPharma logo
NXEN
Nexien BioPharma
0.0$0.14flat$9.87 millionN/A0.00Gap Up
Williston logo
WHCA
Williston
0.0$0.70flat$9.51 millionN/A0.00
GlobeImmune logo
GBIM
GlobeImmune
0.5$1.53flat$8.77 millionN/A0.00Gap Down
ULUR
ULURU
0.3$0.28flat$8.17 millionN/A0.00Decrease in Short Interest
Parnell Pharmaceuticals logo
PARNF
Parnell Pharmaceuticals
0.5$0.36flat$7.20 millionN/A0.00
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08flat$7.15 millionN/A0.00News Coverage
Acura Pharmaceuticals logo
ACUR
Acura Pharmaceuticals
0.6$0.32flat$7.07 million$2.66 million-10.67Gap Up
Bioxytran logo
BIXT
Bioxytran
0.0$0.07flat$7.05 millionN/A0.00Gap Up
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.06flat$6.39 million$30,000.000.00News Coverage
KAYS
Kaya
0.7$0.43flat$6.23 million$1.01 million0.00Gap Up
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.23flat$5.46 million$3.48 million-1.92News Coverage
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.72flat$5.43 million$9.47 million0.00
BCTXF
BriaCell Therapeutics
0.0N/AN/A$4.59 millionN/A-0.01
FutureWorld logo
FWDG
FutureWorld
0.5$0.00flat$4.56 millionN/A0.00
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11flat$4.38 million$3.65 million0.00Decrease in Short Interest
Gap Up
AMBS
Amarantus BioScience
0.0$0.01flat$4.05 millionN/A0.00Increase in Short Interest
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01flat$3.50 millionN/A0.00Increase in Short Interest
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17flat$3.47 millionN/A0.00High Trading Volume
Increase in Short Interest
Gap Up
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04flat$2.84 millionN/A-0.09
NSPX
Inspyr Therapeutics
0.5$0.02flat$2.31 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.16 million$20,000.00-0.97News Coverage
Gap Up
IMUCD
ImmunoCellular Therapeutics
0.0$0.51flat$2.14 millionN/A0.00Gap Up
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00News Coverage
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51flat$1.80 millionN/A0.00Gap Up
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03flat$1.70 million$530,000.000.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.00flat$1.59 million$710,000.000.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02flat$1.52 millionN/A0.00Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.30 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57High Trading Volume
Decrease in Short Interest
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$1.07 millionN/A0.00Increase in Short Interest
Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21flat$1.03 millionN/A0.00Decrease in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03flat$965,000.00N/A0.00Increase in Short Interest
Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$941,000.00N/A0.00Gap Up
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.